uniQure N.V. – NASDAQ:QURE

Add to watchlist

$15.28

-2.22

-12.69%

Market closed

Open in 3 days

+100.69%

month

+100.69%

quarter

+157.35%

year

Market Cap	816.44M
Enterprise value	792.33M

P/E	-7.16
EV/Sales	7.44
EV/EBITDA	-7.33
Price/Sales	8.24
Price/Book	1.84
PEG ratio	0.05
EPS	-6.20

Revenue	19.00M
EBITDA	-244.25M
Income	-296.86M
Revenue Q/Q	59.34%
Revenue Y/Y	-82.72%

Profit margin	-119.07%
Oper. margin	-134.44%
Gross margin	95.18%
EBIT margin	-134.44%
EBITDA margin	-1285.37%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

uniQure N.V. (NASDAQ:QURE): Profit margin
Jun 2023	2.42M	-68.47M	-2827.17%
Sep 2023	1.40M	-89.57M	-6366.1%
Dec 2023	6.68M	-73.20M	-1094.42%
Mar 2024	8.48M	-65.61M	-773.34%

uniQure N.V. Financials Estimate

Q Y

uniQure N.V. (NASDAQ:QURE): Analyst Estimates
Sep 2025	30.84M	-36.43M	-118.13%
Oct 2025	24.38M	-39.39M	-161.59%
Dec 2025	13.89M	-47.40M	-341.15%
Mar 2026	6.50M	-52.86M	-812.21%

Analysts Price target
Financials & Ratios estimates

uniQure N.V. (NASDAQ:QURE): Debt to assets
Jun 2023	942769000	589.44M	62.52%
Sep 2023	871550000	602.76M	69.16%
Dec 2023	831689000	624.01M	75.03%
Mar 2024	770050000	623.29M	80.94%

uniQure N.V. (NASDAQ:QURE): Cash Flow
Jun 2023	-56.99M	45.83M	370.13M
Sep 2023	38.91M	-314.06M	-7.59M
Dec 2023	-49.54M	59.56M	46K
Mar 2024	-60.57M	63.98M	0

uniQure N.V. alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

uniQure N.V. (NASDAQ:QURE): Employee count
Aug 2023	501
Sep 2023	501
Oct 2023	501
Nov 2023	501
Dec 2023	501
Jan 2024	501
Feb 2024	501
Mar 2024	480
Apr 2024	480
May 2024	480
Jun 2024	480
Jul 2024	480

uniQure N.V.
Hedge Funds Holdings Q2 2022

35.13% -45.08%

of QURE is owned by hedge funds

107 -56

hedge funds hold QURE stock

16.37M -21.20M

shares is hold by hedge funds

QURE hedge funds holdings changes

uniQure N.V. (NASDAQ:QURE): Insider trades (number of shares)
Period	Buy	Sel
Feb 2024	0	53265
Jun 2024	0	29851
Dec 2024	0	105214

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Option	10 Dec 2024	KAPUSTA MATTHEW C director, officer..	Ordinary Shares	100,000	$14.71	$1,471,000
Sale	10 Dec 2024	KAPUSTA MATTHEW C director, officer..	Ordinary Shares	100,000	$15.03	$1,503,000
Option	10 Dec 2024	KAPUSTA MATTHEW C director, officer..	Stock Option (Right to Buy)	100,000	$14.71	$1,471,000
Sale	9 Dec 2024	KAPUSTA MATTHEW C director, officer..	Ordinary Shares	3,418	$7.63	$26,079
Sale	9 Dec 2024	KLEMT CHRISTIAN officer: Chief Fi..	Ordinary Shares	1,796	$7.55	$13,560
Sale	26 Jun 2024	ABI-SAAB WALID officer: Chief Medical Officer officer: Chief Medical Officer	Ordinary Shares	1,447	$4.36	$6,309
Sale	17 Jun 2024	CALOZ PIERRE officer: Chief Operating Officer officer: Chief Operating Officer	Ordinary Shares	2,936	$4.81	$14,122
Sale	17 Jun 2024	KLEMT CHRISTIAN officer: Chief Fi..	Ordinary Shares	1,611	$4.8	$7,733
Sale	13 Jun 2024	JACQUES RACHELLE SUZANNE director director	Ordinary Shares	2,221	$5.14	$11,416
Sale	13 Jun 2024	POTTS JEANNETTE officer: Chief Legal Officer officer: Chief Legal Officer	Ordinary Shares	4,781	$4.98	$23,809

uniQure N.V.
Earnings Call Transcripts

Quarter	Transcript
Q3 2015 30 Nov 2015	Q3 2015 Earnings Call Transcript

QURE earnings call transcripts

uniQure N.V.
Executives

Insider	Age	Compensation
Mr. Matthew Craig Kapusta (1972) Chief Executive Officer & Executive Director	53	$965,480
Dr. Alexander E. Kuta Ph.D. (1960) Executive Vice President of Quality & Regulatory	65	$652,580
Dr. Ricardo Dolmetsch Ph.D. (1969) Pres of R&D	56	$626,150
Mr. Christian Klemt (1973) Chief Financial Officer, Principal Financial Officer & GM of Amsterdam Site	52	$392,600

uniQure N.V.
Latest News

Sunday, 15 December 2024
04:31	Up 152% in December, Is uniQure a Good Stock to Buy Now and Hold Through 2025?	fool.com
Wednesday, 11 December 2024
11:06	QURE Soars on FDA Alignment for Speedy Approval of Huntington's Drug	zacks.com
Tuesday, 10 December 2024
07:05	uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington's Disease	globenewswire.com
Friday, 29 November 2024
10:57	Wall Street Analysts Think uniQure (QURE) Could Surge 228.07%: Read This Before Placing a Bet	zacks.com
Thursday, 28 November 2024
13:05	What Makes uniQure (QURE) a New Buy Stock	zacks.com
Thursday, 21 November 2024
07:05	uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy	globenewswire.com
Friday, 8 November 2024
10:55	Wall Street Analysts Believe uniQure (QURE) Could Rally 169.18%: Here's is How to Trade	zacks.com
Tuesday, 5 November 2024
09:31	UniQure (QURE) Reports Q3 Loss, Lags Revenue Estimates	zacks.com
07:05	uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress	globenewswire.com
Tuesday, 29 October 2024
11:06	UniQure (QURE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release	zacks.com
Tuesday, 15 October 2024
07:05	uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS	globenewswire.com
Monday, 23 September 2024
07:05	uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease	globenewswire.com
Thursday, 15 August 2024
07:05	uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease	globenewswire.com
Tuesday, 6 August 2024
03:03	uniQure: Pullback After Strong Interim Treatment Data Creates Buying Opportunity	seekingalpha.com
Thursday, 1 August 2024
09:25	UniQure (QURE) Reports Q2 Loss, Tops Revenue Estimates	zacks.com
07:05	uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update	globenewswire.com
Friday, 26 July 2024
10:55	Wall Street Analysts See a 125.9% Upside in uniQure (QURE): Can the Stock Really Move This High?	zacks.com
Tuesday, 23 July 2024
07:05	uniQure Announces Closing of Sale of Manufacturing Facility to Genezen	globenewswire.com
Friday, 12 July 2024
08:00	What Led To A 150% Rise In UniQure Stock In A Week?	forbes.com
Wednesday, 10 July 2024
10:55	Wall Street Analysts Think uniQure (QURE) Could Surge 195.8%: Read This Before Placing a Bet	zacks.com
10:06	uniQure (QURE) Soars on New Huntington's Disease Study Data	zacks.com
06:50	uniQure (QURE) Surges 76.5%: Is This an Indication of Further Gains?	zacks.com
Tuesday, 9 July 2024
13:48	uniQure: Positive HD AMT-130 Treatment Data Leads To Several Other Catalysts	seekingalpha.com
10:35	Down -29.74% in 4 Weeks, Here's Why You Should You Buy the Dip in uniQure (QURE)	zacks.com
10:27	Why Is uniQure (QURE) Stock Up 51% Today?	investorplace.com
07:05	uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington's Disease	globenewswire.com
Monday, 1 July 2024
07:05	Genezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MA	prnewswire.com
07:05	uniQure Announces Sale of Commercial Manufacturing Facility to Genezen	globenewswire.com
Monday, 3 June 2024
07:05	uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington's Disease	globenewswire.com
Tuesday, 7 May 2024
07:05	uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress	globenewswire.com

Ideas & Opinions

Seeking Alpha 28 May 2025

uniQure's AMT-130 Gene Therapy Warrants An Upgrade
Seeking Alpha 8 May 2025

uniQure: A Buy For Their Lead In Huntington's Program, In Light Of PTC's Data
Seeking Alpha 21 Apr 2025

uniQure: Bullish On Near-Term Catalysts After Breakthrough Therapy Designation For AMT-130
Seeking Alpha 19 Apr 2025

uniQure: AMT-130 For HD Progresses Forward With Q2 2025 FDA Meeting
Seeking Alpha 12 Jul 2024

Undercovered Dozen: Evergy, Navitas Semiconductor, Whirlpool And More
Seeking Alpha 9 Jul 2024

uniQure: Positive HD AMT-130 Treatment Data Leads To Several Other Catalysts
Seeking Alpha 1 Feb 2024

uniQure: The Valuation Got More Attractive
Seeking Alpha 22 May 2023

Market Is Still Not Pricing In The FDA And EU EMA Approvals For uniQure
Seeking Alpha 20 May 2023

uniQure: Financials And Pipeline Signal A Promising Outlook For Investors
Seeking Alpha 18 Feb 2023

uniQure: An FDA Approval, An Advancing Pipeline And A Critical Data Readout

Frequently Asked Questions (FAQ)

What's the price of uniQure N.V. stock today?

One share of uniQure N.V. stock can currently be purchased for approximately $15.28.
When is uniQure N.V.'s next earnings date?

Unfortunately, uniQure N.V.'s (QURE) next earnings date is currently unknown.
Does uniQure N.V. pay dividends?

No, uniQure N.V. does not pay dividends.
How much money does uniQure N.V. make?

uniQure N.V. has a market capitalization of 816.44M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 85.12% to 15.84M US dollars.
What is uniQure N.V.'s stock symbol?

uniQure N.V. is traded on the NASDAQ under the ticker symbol "QURE".
What is uniQure N.V.'s primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of uniQure N.V.?

Shares of uniQure N.V. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are uniQure N.V.'s key executives?
uniQure N.V.'s management team includes the following people:
- Mr. Matthew Craig Kapusta Chief Executive Officer & Executive Director(age: 53, pay: $965,480)
- Dr. Alexander E. Kuta Ph.D. Executive Vice President of Quality & Regulatory(age: 65, pay: $652,580)
- Dr. Ricardo Dolmetsch Ph.D. Pres of R&D(age: 56, pay: $626,150)
- Mr. Christian Klemt Chief Financial Officer, Principal Financial Officer & GM of Amsterdam Site(age: 52, pay: $392,600)
How many employees does uniQure N.V. have?

As Jul 2024, uniQure N.V. employs 480 workers.
When uniQure N.V. went public?

uniQure N.V. is publicly traded company for more then 11 years since IPO on 5 Feb 2014.
What is uniQure N.V.'s official website?

The official website for uniQure N.V. is uniqure.com.
How can i contact uniQure N.V.?

uniQure N.V. can be reached via phone at +31 20 240 6000.

uniQure N.V.

uniqure.com

Exchange:

NASDAQ

Full time employees:

480

Industry:

Biotechnology

Sector:

Healthcare

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

+31 20 240 6000

Paasheuvelweg 25a
Amsterdam, 1105 BP

CIK: 0001590560
ISIN: NL0010696654
CUSIP: N90064101